TNFSF11 and osteosarcoma: Osteoprotegenin, a decoy receptor for receptor activator of nuclear factor kappaB ligand (RANKL), could inhibit bone resorption and osteoclast activity, blocking osteosarcoma progression associated with increased RANKL release [48].